Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Drug Delivery Strategies of Oxidative Stress-Related Diseases
share announcement

Drug Delivery Strategies of Oxidative Stress-Related Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 1215

Special Issue Editors

Prof. Dr. Ethel Antunes Wilhelm

E-Mail Website
Guest Editor
Laboratory in Biochemical Pharmacology, Center of Chemical, Pharmaceutical and Food Sciences, Federal University of Pelotas (UFPel), Pelotas 96160-000, RS, Brazil
Interests: pain; neuropathy; oxidative stress; selenium; inflammation
Dr. Marcel Henrique Marcondes Sari

E-Mail Website
Guest Editor
Clinical Analysis Department, Federal University of Paraná, Curitiba CEP 80210-170, PR, Brazil
Interests: nano-based formulations; cutaneous drug delivery; inflammation; polymeric films;topical drug delivery; hydrogels.
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Oxidative stress runs through the development of several human diseases because it interferes in the physiological functions of living organisms, from the transmission of cell signal proteins to the modulation of ion channels and transporters. Therefore, the regulation of oxidative stress and its signaling pathways is considered to be a promising pharmacological tool for disease treatment.

Thanks to advances in technology, researchers have made progress in a variety of delivery systems and drug formulations with redox-sensitive properties, providing new insights and future directions for clinical research, diagnoses, and treatment for oxidative-stress-related diseases. This Special Issue will highlight:

  • Advances in technology of delivery systems
  • Drug formulations with redox-sensitive properties
  • New drug therapeutic targets for treatment of diseases related to oxidative stress

Prof. Dr. Ethel Antunes Wilhelm
Dr. Marcel Henrique Marcondes Sari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oxidative stress
  • antioxidant
  • nanomedicine 
  • drug delivery 
  • drug design 
  • drug targeting ability 
  • biodistribution 
  • oxidative damage 
  • redox signaling

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

26 pages, 4157 KiB  
Article
4-(Phenylselanyl)-2H-chromen-2-one-Loaded Nanocapsule Suspension—A Promising Breakthrough in Pain Management: Comprehensive Molecular Docking, Formulation Design, and Toxicological and Pharmacological Assessments in Mice
by Caren Aline Ramson da Fonseca, Vinicius Costa Prado, Jaini Janke Paltian, Jean Carlo Kazmierczak, Ricardo Frederico Schumacher, Marcel Henrique Marcondes Sari, Larissa Marafiga Cordeiro, Aline Franzen da Silva, Felix Alexandre Antunes Soares, Robson da Silva Oliboni, Cristiane Luchese, Letícia Cruz and Ethel Antunes Wilhelm
Pharmaceutics 2024, 16(2), 269; https://doi.org/10.3390/pharmaceutics16020269 - 14 Feb 2024
Viewed by 814
Abstract
Therapies for the treatment of pain and inflammation continue to pose a global challenge, emphasizing the significant impact of pain on patients’ quality of life. Therefore, this study aimed to investigate the effects of 4-(Phenylselanyl)-2H-chromen-2-one (4-PSCO) on pain-associated proteins through computational molecular docking [...] Read more.
Therapies for the treatment of pain and inflammation continue to pose a global challenge, emphasizing the significant impact of pain on patients’ quality of life. Therefore, this study aimed to investigate the effects of 4-(Phenylselanyl)-2H-chromen-2-one (4-PSCO) on pain-associated proteins through computational molecular docking tests. A new pharmaceutical formulation based on polymeric nanocapsules was developed and characterized. The potential toxicity of 4-PSCO was assessed using Caenorhabditis elegans and Swiss mice, and its pharmacological actions through acute nociception and inflammation tests were also assessed. Our results demonstrated that 4-PSCO, in its free form, exhibited high affinity for the selected receptors, including p38 MAP kinase, peptidyl arginine deiminase type 4, phosphoinositide 3-kinase, Janus kinase 2, toll-like receptor 4, and nuclear factor-kappa β. Both free and nanoencapsulated 4-PSCO showed no toxicity in nematodes and mice. Parameters related to oxidative stress and plasma markers showed no significant change. Both treatments demonstrated antinociceptive and anti-edematogenic effects in the glutamate and hot plate tests. The nanoencapsulated form exhibited a more prolonged effect, reducing mechanical hypersensitivity in an inflammatory pain model. These findings underscore the promising potential of 4-PSCO as an alternative for the development of more effective and safer drugs for the treatment of pain and inflammation. Full article
(This article belongs to the Special Issue Drug Delivery Strategies of Oxidative Stress-Related Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop